(Q51808830)

12 April 2018

title

Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. (English)

1 reference

12 April 2018

Stenotrophomonas maltophilia

main subject

cystic fibrosis

0 references

1 reference

Denton M

1

1 reference

12 April 2018

Rajgopal A

2

1 reference

12 April 2018

Mooney L

3

1 reference

12 April 2018

Qureshi A

4

1 reference

12 April 2018

Kerr KG

5

1 reference

12 April 2018

Keer V

6

1 reference

12 April 2018

Pollard K

7

1 reference

12 April 2018

Peckham DG

8

1 reference

12 April 2018

Conway SP

9

1 reference

12 April 2018

publication date

1 November 2003

1 reference

12 April 2018

Journal of Hospital Infection

published in

1 reference

12 April 2018

volume

55

1 reference

12 April 2018

issue

3

1 reference

12 April 2018

page(s)

180-183

1 reference

12 April 2018

Microbiology of sputum from patients at cystic fibrosis centers in the United States

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2803%2900299-8

7 January 2021

10.1016/S0195-6701(03)00299-8

Identifiers

DOI

1 reference

12 April 2018

PubMed ID

14572484

1 reference

12 April 2018